Resumen

CABEZUELO, Juan B. et al. Infliximab in the treatment of amyloidosis secondary to Crohn's disease. Nefrología (Madr.) [online]. 2012, vol.32, n.3, pp.385-388. ISSN 1989-2284.

Secondary amyloidosis (AA) is a severe complication of progressed Crohn's disease (CD) for which no effective treatment exists. We present the exceptional case of a 33 year-old male with moderate renal failure and proteinuria, who was simultaneously diagnosed with AA amyloid nephropathy and oligosymptomatic CD. He was treated with infliximab at 5mg/kg/8 weeks for 4 years, azathioprine at 1-1.5mg/kg/day (first year) and renin-angiotensin-aldosterone system blockers, with no complications. Treatment caused a decrease in proteinuria, improved renal function, and improved inflammatory parameters over time. Inspired by this case, we performed a review of the medical literature and found that infliximab could be a useful tool in the early treatment of amyloidosis secondary to CD.

Palabras clave : Infliximab; Secondary amyloidosis; Crohn's disease.

        · resumen en Español     · texto en Español     · Español ( pdf )